Pharma BD Deal Intelligence

Pfizer Inc. / Therachon Holding AG

2019 · Acquisition/Merger · $810M · Complete

A bust: Pfizer paid ~$810M for Therachon's FGFR3 decoy TA-46, betting it could out-develop BioMarin's vosoritide, but the Phase 2 study was terminated in November 2022 for lack of efficacy at any dose, and Pfizer shelved the program entirely by January 2023.

Outcome grade pending — assessed 5 years post-close.

Full analysis, sources & comparables →

The coverage arc

May 08, 2019 BioSpace Bullish

Pfizer CSO Mikael Dolsten: 'By acquiring Therachon, we hope to leverage Pfizer's leading scientific and development capabilities to more rapidly advance this…

May 08, 2019 Pharmaphorum Bullish

TA-46 is a recombinant FGFR3 decoy administered weekly subcutaneously; Pfizer to compete directly with BioMarin's vosoritide which has 'caught analysts' eyes'…

Mar 27, 2023 ClinicalTrials.gov (NCT04638153) Bearish

Phase 2 study of recifercept in children with achondroplasia. Overall status: TERMINATED. Why stopped: 'The study was terminated due to lack of efficacy at any…

Source summaries from our enrichment pipeline; follow links for originals.

All 6 sources with sentiment breakdown →

Pfizer agreed to acquire Swiss clinical-stage biotech Therachon Holding AG for $340M upfront plus up to $470M in development milestones (~$810M total); announced 13-Feb-2019 and closed 1-Jul-2019. The lead asset, TA-46 (later named recifercept), is a soluble recombinant human FGFR3 decoy designed to sequester FGF ligands extracellularly and normalize overactive FGFR3 signaling in achondroplasia — a mechanism distinct from BioMarin's CNP-analog vosoritide (VOXZOGO). Pfizer divested Therachon's secondary FGF21 short-bowel-syndrome program back to the founders. The thesis ultimately did not pan out: Pfizer's Phase 2 study of recifercept in children (NCT04638153) was terminated on 18-Nov-2022 for lack of efficacy at all tested doses (not a safety concern), and Pfizer formally discontinued the recifercept achondroplasia program on 31-Jan-2023 amid a broader pipeline thinning — leaving BioMarin's VOXZOGO uncontested among approved achondroplasia therapies.

Did it work? Outcome assessment

Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pfizer paid $340M upfront with up to $470M in contingent milestone payments. The lead asset's Phase 2 failure means the milestone payments were not triggered, and the acquired achondroplasia program was terminated, effectively writing off the value of the deal's core rationale.
Pipeline outcome
Assets Terminated
Therachon's lead asset TA-46, renamed recifercept (a soluble recombinant FGFR3 decoy for achondroplasia), failed a planned Phase 2 interim analysis that showed it would not meet the primary efficacy endpoint. Pfizer terminated development on November 18, 2022, citing lack of efficacy at all tested doses (not safety). The discontinuation came as Pfizer rethought its rare-disease R&D.

Key facts

Disease & market context

Achondroplasia

Disease Overview

Achondroplasia is the most common form of short-limbed skeletal dysplasia (dwarfism), caused in >95% of cases by a single G1138A point mutation in the FGFR3 gene that produces constitutively active receptor signaling and impaired endochondral ossification. Beyond short stature, patients face serious cardiovascular, neurological (foramen magnum stenosis), and metabolic complications; over 80% of cases arise from spontaneous mutations to average-stature parents.

Competitive Landscape

At deal close (May 2019), achondroplasia had no approved disease-modifying therapy. BioMarin's vosoritide (BMN 111), a CNP analog that inhibits intracellular FGFR3 signaling downstream, was the clear front-runner — Phase 3 enrolling, eventually FDA-approved as VOXZOGO in November 2021 for children ≥5 (label later expanded to under 5). QED Therapeutics/BridgeBio's infigratinib, an oral pan-FGFR small-molecule inhibitor, was in early development and later progressed to Phase 3. Ascendis Pharma's TransCon CNP (navepegritide) entered Phase 2 as a long-acting CNP. Pfizer's $340M upfront / $470M milestones / ~$810M total bet on Therachon's TA-46 was a Phase 1 soluble FGFR3 decoy receptor — a fundamentally different mechanism that sequesters FGF ligands extracellularly rather than blocking downstream signaling. Both Pfizer and BioMarin held FDA/EMA Orphan Drug Designations. Pfizer divested Therachon's secondary FGF21-based short-bowel-syndrome program back to Therachon's founders. Pfizer ultimately discontinued the TA-46 program in 2023 after Phase 2 readouts, leaving BioMarin's VOXZOGO uncontested in the approved-therapy space.

Deal timeline

Related deals — scored

DealYearValueOutcome
Pfizer Inc. / Therachon Holding AG (this deal)2019$810M
Pfizer Inc. / BioNTech SE2020$748M100
Pfizer Inc. / FoldRx Pharmaceuticals201099
Pfizer Inc. / Medivation Inc.2016$14.0B86
Pfizer Inc. / Wyeth2009$68.0B86
Pfizer Inc. / Warner-Lambert Company2000$90.0B83
Pfizer Inc. / Arvinas, Inc.2021$2.4B77

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →